Your session is about to expire
← Back to Search
Caregiver Training with MapHabit for Alzheimer's Disease
Study Summary
This trial will study whether or not a new Alzheimer's disease technology called MapHabit, which uses visual maps to improve a patient's behavior and sense of autonomy, can reduce caregiver burden when used with a caregiver training program. A total of 50 patient-caregiver dyads will be studied over a 6-month period, with half receiving MapHabit and half receiving usual care.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not fluent in English.I have been diagnosed with Alzheimer's or similar dementia at a mild to moderate stage.I have not been diagnosed with Alzheimer's or related dementias.
- Group 1: Caregiver Training Program
- Group 2: The MapHabit System
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What primary goals are being pursued by this medical experiment?
"The primary endpoint of this trial will be a measure of the Zarit Burden Assessment Caregiver Strain instrument, conducted before and after 6 months. Secondary assessments include changes in pain levels via the Pain and Sleep Questionnaire, Generalized Anxiety Disorder (GAD7) Scale to evaluate generalised anxiety disorder symptoms, as well as the 2-item Satisfaction Scale (SS-2), which gauges patient satisfaction with their MHS experience."
Is the application window for this clinical trial still open to prospective participants?
"According to information available on clinicaltrials.gov, this particular trial is closed for recruitment as of September 1st 2022. Originating from February 1st 2024, the study has since concluded its candidate search; however, there are 796 other trials that are actively inviting participants at this time."
Share this study with friends
Copy Link
Messenger